Brief: Enliven Therapeutics Appoints Kristine Ball To Board Of Directors Ahead Of Planned Phase 3 Trial Initiation This Year
14/10/2026 22:07
BRIEF-Enliven Therapeutics Appoints Kristine Ball To Board Of Directors Ahead Of Planned Phase 3 Trial Initiation This Year Oct 14 (Reuters) - Enliven Therapeutics, Inc. ELVN.O:
ENLIVEN THERAPEUTICS APPOINTS KRISTINE BALL TO BOARD OF DIRECTORS AHEAD OF PLANNED PHASE 3 TRIAL INITIATION THIS YEAR
Source text: ID:nPnbfTd6qa
Further company coverage: ELVN.O
((((Reuters.Briefs@thomsonreuters.com;));))
Recent news on Enliven Therapeutics
See all newsBrief: Enliven Therapeutics Appoints Kristine Ball To Board Of Directors Ahead Of Planned Phase 3 Trial Initiation This Year
US RESEARCH ROUNDUP-Amrize, Dexcom, Lennar
U.S. RESEARCH ROUNDUP- Berkshire Hathaway, Exxon Mobil, Honeywell Technologies
U.S. RESEARCH ROUNDUP-Caterpillar, Eli Lilly, McKesson
Enliven Therapeutics Q2 net loss widens on higher expenses